NRAS and cancer: It was observed that 41 NRAS-mutant cancer cell lines were commonly responsive to 10 drugs, namely PD-0325901, Trametinib, Selumetinib, TL-1-85, CI-1040, NG-25, PLX4720, AP-24534 (Ponatinib), Xl-184 (Cabozantinib) and Foretinib.